Boule Diagnostics AB (BDABF) Stock Price & Analysis

BDABF Stock Chart & Stats

No data to display

Day’s Range: N/A
52-Week Range: N/A
Previous Close: N/A
Volume: N/A
Average Volume (3M): N/A
Market Cap: $4.10M
Enterprise Value: $293.09M
Total Cash (Recent Filing): $13.50M
Total Debt (Recent Filing): $216.50M
Price to Earnings (P/E): ―
Beta: N/A
Next Earnings: Feb 10, 2027 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Recurring Consumables Model

The installed-base model can create recurring consumables revenue after analyzer placement, improving customer retention and revenue visibility. Service and support activities add another ongoing revenue stream, giving Boule a durable monetization layer beyond one-time instrument sales.

Resilient Gross Margin

Maintaining gross margin near 43–45% despite weaker revenue and operating performance indicates that the underlying product economics have not fully deteriorated. This provides a foundation for future margin recovery if sales stabilize and fixed costs are better absorbed.

Improving Cash Generation

The recent rebound in operating cash flow and return to positive free cash flow improve Boule’s ability to fund operations internally. If sustained, this could reduce dependence on external financing and support investment in its analyzer platform and installed base.

Bears Say

Sustained Revenue Decline

Three consecutive periods of declining revenue signal persistent pressure on demand, pricing, or market execution rather than a single-quarter setback. Continued contraction can weaken scale benefits, reduce reinvestment capacity, and make recovery in operating profitability more difficult.

Persistent Losses

Sustained net losses show that Boule has not converted its medical technology offering into dependable earnings in recent periods. Ongoing losses can constrain strategic flexibility, consume equity, and make the recent improvement in cash flow less convincing until profitability returns.

Higher Leverage

Higher debt relative to a shrinking equity base reduces financial flexibility and increases the burden on future operating cash flow. This leaves less capacity to absorb continued volatility or fund growth internally, particularly while accounting losses remain unresolved.

Boule Diagnostics AB News

Boule Diagnostics Hit by Instrument Shortfall but Recurring Revenues Hold Margins

Boule Diagnostics AB ( ($SE:BOUL) ) has shared an announcement. Boule Diagnostics AB reported a weak third quarter, as group net sales fell 24.4 percent to SEK 96.2 million due

1w agoBDABF BOUL

Boule Diagnostics Deepens Strategic Partnership to Drive Growth in Indian Diagnostics Market

The latest update is out from Boule Diagnostics AB ( ($SE:BOUL) ). Boule Diagnostics AB has updated its licensing agreement with long-time partner Q-Line Biotech Limited covering diagnostic reagents, consumables,

3w agoBDABF BOUL

Boule Diagnostics Secures Shareholder Loan at Extraordinary Meeting

Boule Diagnostics AB ( ($SE:BOUL) ) has provided an announcement. Boule Diagnostics AB, a global provider of near‑patient human and veterinary diagnostic instruments, reagents, and controls, operates through its Diagnostics

2M agoBDABF 0P4Z

Boule Diagnostics Battles Geopolitical Headwinds as New CEO Steps In

An update from Boule Diagnostics AB ( ($SE:BOUL) ) is now available. Boule Diagnostics AB reported a difficult second quarter of 2026, with net sales falling 13.3 percent to SEK

3M agoBDABF 0P4Z

Boule Diagnostics Names Johan Folkunger as New CEO to Lead Next Growth Phase

Boule Diagnostics AB ( ($SE:BOUL) ) just unveiled an announcement. Boule Diagnostics has appointed Johan Folkunger as its new chief executive officer, effective 22 June 2026, succeeding interim CEO Simonetta

4M agoBDABF 0P4Z

Boule Diagnostics Names Simonetta Tumbiolo Interim CEO as Nielsen Steps Down

Boule Diagnostics AB ( ($SE:BOUL) ) has issued an update. Boule Diagnostics has appointed Chief Commercial Officer Diagnostic Simonetta Tumbiolo as interim chief executive officer, effective 1 June 2026, following

5M agoBDABF 0P4Z

BDABF Earnings this Week: How Will it Perform?

Boule Diagnostics AB (BDABF) is scheduled to report 3rd quarter earnings on 10/25/2024, before the market opens. Regarding Q3 estimates, Wall Street analysts expect Boule Diagnostics AB to post earnings

2y agoBDABF 8BD

Is BDABF a Buy, Before Earnings?

Boule Diagnostics AB (BDABF) is scheduled to report 2nd quarter earnings on 07/22/2024, before the market opens. Regarding Q2 estimates, Wall Street analysts expect Boule Diagnostics AB to post earnings

2y agoBDABF 8BD

BDABF Earnings this Week: How Will it Perform?

Boule Diagnostics AB (BDABF) is scheduled to report 4th quarter earnings on 02/06/2024, before the market opens. Regarding Q4 estimates, Wall Street analysts expect Boule Diagnostics AB to post earnings

2y agoBDABF 8BD

Is BDABF a Buy, Before Earnings?

Boule Diagnostics AB (BDABF) is scheduled to report 2nd quarter earnings on 07/24/2023, before the market opens. Regarding Q2 estimates, Wall Street analysts expect Boule Diagnostics AB to post earnings

3y agoBDABF 8BD

BDABF FAQ

What is Boule Diagnostics AB’s market cap?

Boule Diagnostics AB’s market cap is $4.10M.

When is Boule Diagnostics AB’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Boule Diagnostics AB’s earnings last quarter?

Boule Diagnostics AB released its earnings results on Oct 23, 2026. The company reported -$0.007 earnings per share for the quarter, missing the consensus estimate of -$0.002 by -$0.004.

Is Boule Diagnostics AB overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Boule Diagnostics AB pay dividends?

Boule Diagnostics AB does not currently pay dividends.

What is Boule Diagnostics AB’s EPS estimate?

Boule Diagnostics AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Boule Diagnostics AB have?

Boule Diagnostics AB has 38,833,103 shares outstanding.

What happened to Boule Diagnostics AB’s price movement after its last earnings report?

Boule Diagnostics AB reported an EPS of -$0.007 in its last earnings report, missing expectations of -$0.002. Following the earnings report the stock price went same ―.

Which hedge fund is a major shareholder of Boule Diagnostics AB?

Currently, no hedge funds are holding shares in BDABF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description